Product
AP1903
5 clinical trials
17 indications
Indication
lymphomaIndication
B-cellIndication
Immune System DiseasesIndication
Immunoproliferative DisordersIndication
Lymphatic DiseasesIndication
Acute Lymphoblastic LeukemiaIndication
Myelodysplastic SyndromeIndication
Acute Myeloid LeukemiaIndication
B-Lymphoid MalignanciesIndication
Acute Lymphocytic LeukemiaIndication
Chronic Lymphocytic LeukemiaIndication
Non-Hodgkin LymphomaIndication
Breast CancerIndication
SarcomaIndication
OsteosarcomaIndication
NeuroblastomaIndication
MelanomaClinical trial
A Phase I Study of Autologous Activated T-cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch in Subjects With Relapsed/Refractory B-cell LymphomaStatus: Recruiting, Estimated PCD: 2027-03-22
Clinical trial
Administration of Haploidentical Donor T Cells Transduced With the Inducible Caspase-9 Suicide GeneStatus: Active (not recruiting), Estimated PCD: 2029-05-01
Clinical trial
Dose Escalation Study Phase I/II of Umbilical Cord Blood-Derived CAR-Engineered NK Cells in Conjunction With Lymphodepleting Chemotherapy in Patients With Relapsed/Refractory B-Lymphoid MalignanciesStatus: Completed, Estimated PCD: 2023-03-06
Clinical trial
A Phase I Clinical Trial to Evaluate the Safety and Tolerability of Mesothelin-Specific Chimeric Antigen Receptor-Positive T Cells in Patients With Metastatic Mesothelin-Expressing Breast CancerStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid TumorsStatus: Completed, Estimated PCD: 2016-08-15